Approaches to manage 'affordability' of high budget impact medicines in key EU countries
{{output}}
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mec... ...
